$3.20
3.61% yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
US6821431029
Symbol
OMER
Sector
Industry

Omeros Corporation Stock price

$3.20
+0.03 0.95% 1M
-8.48 72.60% 6M
-6.68 67.61% YTD
-0.75 18.99% 1Y
+0.02 0.63% 3Y
-11.27 77.89% 5Y
-15.09 82.50% 10Y
-5.53 63.34% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.12 3.61%
ISIN
US6821431029
Symbol
OMER
Sector
Industry

Key metrics

Basic
Market capitalization
$187.5m
Enterprise Value
$532.1m
Net debt
$344.6m
Cash
$52.4m
Shares outstanding
58.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 68.93
EV/Sales
- | 195.64
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-65.91%
Return on Equity
85.98%
ROCE
-108.62%
ROIC
-
Debt/Equity
-1.86
Financials (TTM | estimate)
Revenue
$0.0 | $2.7m
EBITDA
$-164.0m | $-43.2m
EBIT
$-165.0m
Net Income
$-153.1m | $-112.3m
Free Cash Flow
$-142.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-0.76% | 74.28%
EBIT
-0.81%
Net Income
-26.37% | 28.48%
Free Cash Flow
-0.34%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,588.87%
EBIT
-
Net
- | -4,128.07%
Free Cash Flow
-
More
EPS
$-2.63
FCF per Share
$-2.46
Short interest
23.38%
Employees
202.00
Rev per Employee
$0.00
Show more

Is Omeros Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Omeros Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Omeros Corporation forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Omeros Corporation forecast:

Buy
70%
Hold
30%

Financial data from Omeros Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
4% 4%
-
- Research and Development Expense 117 117
0% 0%
-
-164 -164
1% 1%
-
- Depreciation and Amortization 1.04 1.04
12% 12%
-
EBIT (Operating Income) EBIT -165 -165
1% 1%
-
Net Profit -153 -153
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about Omeros Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omeros Corporation Stock News

Neutral
Business Wire
one day ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as an...
Neutral
Business Wire
4 days ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 27, 2025, starting at 10:00 a.m. Pacific Time. The live webcast can be accessed through the virtual shareholder meeting website at www.virtualshareholdermeeting.com/OMER2025. A general corporate ...
Neutral
Seeking Alpha
about one month ago
Omeros' recent convertible note exchange highlights severe liquidity issues and questionable creditworthiness, leading to a sharp stock decline. Despite reducing near-term debt obligations, Omeros faces a significant cash burn, with only $52.5 million in cash as of March 2025. The company's cash runway is dangerously short, likely lasting only until late summer 2025, necessitating urgent financ...
More Omeros Corporation News

Company Profile

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Head office United States
CEO Gregory Demopulos
Employees 202
Founded 1994
Website www.omeros.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today